Merck KGaA, Darmstadt, Germany

624 articles about Merck KGaA, Darmstadt, Germany

• Sparking Curiosity Across the U.S. With MilliporeSigma’s Curiosity Cube

  9/20/2023

  The Curiosity Cube, a 22x10-foot shipping container turned mobile science lab from MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has been hard at work sparking kids' interest in STEM careers on its fifth annual U.S tour.

• Merck KGaA, Darmstadt, Germany, Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery

  9/20/2023

  Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence -driven design and discovery capabilities, further advancing the company’s research efforts.

• Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany

  9/20/2023

  Exscientia plc announced a new collaboration with Merck KGaA, Darmstadt, Germany focused on the discovery of novel small molecule drug candidates across oncology, neuroinflammation and immunology.

• MilliporeSigma Leaders Receive Business Intelligence Group Sustainability Awards

  9/18/2023

  In recognition of their contributions to sustainable business practices, two leaders from MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, were selected as recipients in the Business Intelligence Group 2023 Sustainability Awards program.

• Breaking New Ground: Merck KGaA, Darmstadt, Germany’s Major Life Science Solar Energy Initiative Powers Up at Darmstadt Site

  7/24/2023

  By 2030, Merck KGaA, Darmstadt, Germany's sustainability strategy aims for a 50% reduction in Scope 1 and Scope 2 emissions as compared to 2020.

• First Patient Dosed in STARSTRUCK Study of TLX250 Targeted Radiation Therapy in Combination with Merck Investigational DNA-PK Inhibitor, Peposertib

  7/18/2023

  Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase I study of the Company's investigational targeted radiation therapy, TLX250, in combination with a Merck KGaA, Darmstadt, Germany (Merck) DNA-dependent protein kinase (DNA-PK) inhibitor candidate, peposertib (M3814).

• Merck KGaA, Darmstadt, Germany Partners with Veeva to Transform Medical Information Operations Globally

  7/12/2023

  Veeva Systems (NYSE: VEEV) today announced that Merck KGaA, Darmstadt, Germany is using Veeva Vault MedInquiry as its global medical information management system.

• U.S. Businesses of Merck KGaA, Darmstadt, Germany, Named a 'Best Place to Work for Disability Inclusion'

  7/11/2023

  Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that its U.S. businesses have been named a "Best Place to Work for Disability Inclusion" by the Disability Equality Index®, recognized as the most comprehensive benchmarking tool for the Fortune 1000 and Am Law 2001 to measure disability workplace inclusion against competitors.

• 

  MoonLake Looks to Raise $250M in Stock Offering on Heels of Mid-Stage Data

  6/27/2023

  Phase II results of MoonLake’s sonelokimab suggest superiority to the competition. Funds raised in the stock offering will support Phase III trials with an anticipated launch in 2027.

• Curia Expands Cell Line Development Offering with CHOZN PlatformCuria signs license agreement with MilliporeSigma to support production of proteins and antibodies

  6/20/2023

  Curia today announced it has signed a licensing agreement with MilliporeSigma, the North American Life Sciences Business of Merck KGaA, Darmstadt, Germany, that enables Curia and its clients to use the CHOZN® GS-/- cell line for production of therapeutic proteins and antibodies.

• Innovent Enters into Clinical Trial Collaboration with Merck KGaA, Darmstadt, Germany Investigating Combination Therapy of IBI351 (KRASG12C Inhibitor) and Cetuximab (ERBITUX®)for KRASG12C-mutated NSCLC in China

  6/1/2023

  Innovent Biologics, Inc. ("Innovent") (HKEX: 01801) today announced that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany for the combination therapy of IBI351 (GFH925) with cetuximab (ERBITUX®) as a potential frontline treatment for NSCLC patients harboring KRASG12C mutation in a Phase 1b clinical trial in China.

• 

  Industry Seeks to Stimulate Innovation Through Grant Programs

  5/3/2023

  In addition to promoting their brands, companies say their funding initiatives give them access to the expertise of top researchers and contribute to society.

• The Life Science Business of Merck KGaA, Darmstadt, Germany Signature Partnerships Advance Access to Science Education

  4/27/2023

  Building on its focus to spark curiosity in the next generation of scientists and accelerate global access to science, MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announces eight new and expanded Signature Partnerships for 2023-2025.

• MilliporeSigma Kicks Off 2023 Curiosity Cube Mobile Lab Tour

  4/26/2023

  MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has kicked off its 2023 Curiosity Cube tour in North America and Europe.

• MilliporeSigma Ranks on EPA’s National Top 100 List of Green Power Users

  4/24/2023

  MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced it placed No. 64 on the U.S. Environmental Protection Agency's National Top 100 List of the largest green power users within the EPA's Green Power Partnership program.

• Merck & XtalPi Collaboration Optimizes Drug Formulations with AI-Powered Techniques

  4/14/2023

  Science and technology company Merck and XtalPi Inc., a pioneering pharmaceutical technology company powered by artificial intelligence (AI) and automation, have jointly published a study that highlights the benefits of combining computational workflows with wet lab experiments to advance drug development.

• Initiation of New Patients on Evobrutinib Paused in the U.S.; Fully Enrolled Phase III Evobrutinib Studies Continue

  4/12/2023

  Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced the U.S. Food and Drug Administration has placed a partial clinical hold on the initiation of new patients on evobrutinib and patients with less than 70 days exposure to study medication in the U.S.

• Merck KGaA, Darmstadt, Germany Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab)

  3/27/2023

  Merck KGaA, Darmstadt, Germany regains exclusive worldwide rights to develop, manufacture and commercialize BAVENCIO from Pfizer.

• EMD Serono Highlights New Four-Year Efficacy and Safety Data for Investigational BTK Inhibitor, Evobrutinib, in RMS

  2/23/2023

  EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced updated long-term efficacy and safety data for investigational evobrutinib that continue to show a favorable safety and tolerability profile, consistent with what was seen earlier in the double-blind period (DBP) of the clinical trials.

• New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma

  2/13/2023

  EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced findings of a new analysis of long-term follow-up data from the Phase III JAVELIN Bladder 100 trial.